- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05911399
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency
Expanded Access Program for Tiratricol in Patients With Monocarboxylate Transporter 8 Deficiency Also Known as Allan-Herndon-Dudley Syndrome (AHDS)
Study Overview
Status
Intervention / Treatment
Detailed Description
This will be an open-label, single-arm, multi-center EAP, designed to provide treatment access in the US to tiratricol for eligible patients with MCT8 deficiency, also known as AHDS.
Patients will undergo clinical and safety assessments before tiratricol treatment initiation, during the titration phase and then at approximately 3-6 monthly intervals or more frequently if clinically indicated, following the initiation of tiratricol treatment and until treatment is completed or discontinued.
Adverse events (AEs) and serious adverse events (SAEs) will be recorded and reported as per FDA regulations.
Study Type
Expanded Access Type
- Individual Patients
- Treatment IND/Protocol
Contacts and Locations
Study Contact
- Name: Egetis Therapeutics
- Email: medical@egetis.com
Study Contact Backup
- Name: AnovoRx
- Phone Number: +1-866-669-5659
- Email: EgetisEAP@anovorx.com
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35249
- Available
- University of Alabama At Birmingham Hospital
-
Contact:
- Leen Matalka, MD
-
-
California
-
Madera, California, United States, 93636-8762
- Available
- Valley Children's Hospital
-
Contact:
- Richard Sidlow, MD
-
San Diego, California, United States, 92123
- Available
- Rady Children's Hospital
-
Contact:
- Michael Gottschalk, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Available
- Children's Hospital of Philadelphia
-
Contact:
- Andrew Bauer, MD
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Available
- Le Bonheur Children's Hospital Foundation
-
Contact:
- Jordan Ross, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Each patient must meet all of the following criteria to be eligible:
- Diagnosis of MCT8 deficiency confirmed with a genetic test.
- Either tiratricol treatment naïve, or patients who may be on a stable dose of tiratricol having transferred from the Phase 3 MCT8-2021-3 (ReTRIACt) study (NCT05579327) or prior individual investigational new drug (IND).
- In the Treating Physician's medical opinion, the potential benefits of treatment with tiratricol outweigh the potential risks for the patient.
- Patient or legal representative provided signed and dated informed consent to be treated with tiratricol, through this EAP.
- Given the severity of the disease, sexual activity in these patients is deemed unlikely. However, where, at the discretion of the Treating Physician sexual activity is possible for the patient, patients must follow protocol-specified-contraception guidance.
- Patient is approved for enrolment by the sponsor RTT.
Exclusion Criteria:
Patients who meet any of the following criteria will be excluded from the EAP:
- Parents, legal representative or, if applicable, patients unwilling or unable to comply with the Treating Physician's treatment plan related to this EAP for any reason.
Major illness or recent major surgery unrelated to MCT8 deficiency (in the Treating Physician's judgement), defined as:
- Conditions requiring repeated hospitalizations that are likely to confound ability to participate in the program.
- Major illness in the 3 months before the screening visit that is likely to confound the ability of the patient to participate fully within the program and/or confound the assessment of serum total T3 and/or safety.
- Major surgery within the 3 months before the screening visit, or planned to take place during the program, including but not limited to major abdominal/thoracic/neurosurgical procedures.
- Major/minor abdominal and/or maxillofacial surgery that may inhibit the administration and/or absorption of tiratricol.
- Patients with any contra-indication for treatment with tiratricol or any excipients in the program treatment.
- Patients using thyroid hormone analogues- such as levothyroxine -or thionamides, such as propylthiouracil. Prior use of these drugs is not an exclusion criterion, provided the use of the medication has subsided and the thyroid hormone levels have stabilized after the cessation of these medications. For patients currently using these medications the switch to tiratricol should be made following the above and under the guidance of an endocrinologist with knowledge of MCT8 deficiency, if needed, after consultation with pharmacologist.
- Known hypersensitivity to tiratricol including any ingredient in the pharmaceutical formulation.
- Although very unlikely, as this is a severe X-linked disease: Women who are nursing or pregnant (or women who are planning to become pregnant during treatment with tiratricol).
- Patients eligible for clinical trials with tiratricol.
Study Plan
How is the study designed?
Collaborators and Investigators
Publications and helpful links
General Publications
- Groeneweg S, Peeters RP, Moran C, Stoupa A, Auriol F, Tonduti D, Dica A, Paone L, Rozenkova K, Malikova J, van der Walt A, de Coo IFM, McGowan A, Lyons G, Aarsen FK, Barca D, van Beynum IM, van der Knoop MM, Jansen J, Manshande M, Lunsing RJ, Nowak S, den Uil CA, Zillikens MC, Visser FE, Vrijmoeth P, de Wit MCY, Wolf NI, Zandstra A, Ambegaonkar G, Singh Y, de Rijke YB, Medici M, Bertini ES, Depoorter S, Lebl J, Cappa M, De Meirleir L, Krude H, Craiu D, Zibordi F, Oliver Petit I, Polak M, Chatterjee K, Visser TJ, Visser WE. Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019 Sep;7(9):695-706. doi: 10.1016/S2213-8587(19)30155-X. Epub 2019 Jul 31.
- van Geest FS, Groeneweg S, van den Akker ELT, Bacos I, Barca D, van den Berg SAA, Bertini E, Brunner D, Brunetti-Pierri N, Cappa M, Cappuccio G, Chatterjee K, Chesover AD, Christian P, Coutant R, Craiu D, Crock P, Dewey C, Dica A, Dimitri P, Dubey R, Enderli A, Fairchild J, Gallichan J, Garibaldi LR, George B, Hackenberg A, Heinrich B, Huynh T, Klosowska A, Lawson-Yuen A, Linder-Lucht M, Lyons G, Monti Lora F, Moran C, Muller KE, Paone L, Paul PG, Polak M, Porta F, Reinauer C, de Rijke YB, Seckold R, Menevse TS, Simm P, Simon A, Spada M, Stoupa A, Szeifert L, Tonduti D, van Toor H, Turan S, Vanderniet J, de Waart M, van der Wal R, van der Walt A, van Wermeskerken AM, Wierzba J, Zibordi F, Zung A, Peeters RP, Visser WE. Long-Term Efficacy of T3 Analogue Triac in Children and Adults With MCT8 Deficiency: A Real-Life Retrospective Cohort Study. J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1136-e1147. doi: 10.1210/clinem/dgab750.
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Intellectual Disability
- Heredodegenerative Disorders, Nervous System
- Atrophy
- Syndrome
- Muscular Atrophy
- Muscle Hypotonia
- Mental Retardation, X-Linked
Other Study ID Numbers
- Tiratricol-EAP-Pro MCT8-2022-4
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Monocarboxylate Transporter 8 Deficiency
-
Kaplan Medical CenterWeizmann Institute of ScienceRecruitingMonocarboxylate Transporter 8 DeficiencyIsrael
-
Rare Thyroid Therapeutics International ABPremier Research Group plc; Egetis TherapeuticsRecruitingMonocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley SyndromeUnited States, United Kingdom, Netherlands
-
Rare Thyroid Therapeutics International ABVitaccess LtdCompletedAllan-Herndon-Dudley Syndrome | Monocarboxylate Transporter 8 (MCT8) DeficiencyUnited Kingdom
-
Karen Lindhardt MadsenRigshospitalet, DenmarkCompletedCarnitine Transporter, Plasma-membrane, Deficiency of
-
Hospices Civils de LyonRecruitingCreatine Transporter DefectFrance
-
Irina A AnselmNo longer availableCitrate Transporter Deficiency | SLC13A5 Gene MutationUnited States
-
University of California, San FranciscoCompletedCarnitine Transporter DeficiencyUnited States
-
Juan PascualCompletedGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency SyndromeUnited States
-
Juan PascualWithdrawnGlucose Transporter Type 1 Deficiency Syndrome | Glut1 Deficiency SyndromeUnited States
-
University of Texas Southwestern Medical CenterRecruitingGlucose Transporter Type 1 Deficiency Syndrome | GLUT1 Deficiency Syndrome | Glucose Transporter type1 (GLUT-1) Deficiency | GLUT-1 Deficiency SyndromeUnited States
Clinical Trials on Tiratricol
-
Rare Thyroid Therapeutics International ABPremier Research Group plc; Egetis TherapeuticsRecruitingMonocarboxylate Transporter 8 Deficiency | Allan-Herndon-Dudley SyndromeUnited States, United Kingdom, Netherlands
-
Rare Thyroid Therapeutics International ABErasmus Medical CenterActive, not recruitingAllan-Herndon-Dudley SyndromeUnited States, Netherlands, Czechia, Germany
-
Erasmus Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedAllan-Herndon-Dudley SyndromeNetherlands